PPAR Targeted Drug Candidate for Obesity, Diabetes and Neurodegeneration

Target Name: RABGGTA

NCBI ID: G5875

RABGGTA

PPAR Targeted Drug Candidate for Obesity, Diabetes and Neurodegeneration

RABGGTA (PRTX-067485) is a drug candidate targeting the protein known as PPAR未 (permeable receptor subfamily G protein-coupled receptor family 未), which is a key regulator of lipid metabolism and inflammation. PPAR未 is a transmembrane protein that plays a crucial role in the development and progression of diseases such as obesity, type 2 diabetes, and cardiovascular disease.

RABGGTA is a small molecule inhibitor of PPAR未, which blocks the activity of the protein and inhibits the production of the hormone adenosine. Adenosine is a well-known immune and inflammatory system modulator that has been shown to play a key role in the regulation of inflammation and inflammation-related diseases.

The PPAR未 protein is expressed in many different tissues and cells in the body, including tissues involved in energy metabolism, such as the liver and muscle. It is also expressed in the brain, where it is involved in the regulation of stress and anxiety responses.

The PPAR未 protein is known to play a key role in the regulation of lipid metabolism, as it is involved in the production and uptake of fatty acids into the liver. It is also involved in the regulation of glucose metabolism and insulin sensitivity, which are important factors in the development of type 2 diabetes.

In addition to its role in lipid metabolism, PPAR未 is also involved in the regulation of inflammation and stress responses. It has been shown to play a key role in the regulation of inflammation in the body, and is involved in the production of pro-inflammatory cytokines.

The development of PPAR未 as a drug target is an exciting area of research, as it has the potential to treat a wide range of diseases. Obesity, type 2 diabetes, and cardiovascular disease are some of the most common diseases that are associated with PPAR未 dysfunction.

In addition to its potential use in treating obesity and type 2 diabetes, PPAR未 has also been shown to have potential in treating other diseases. For example, it has been shown to have anti-inflammatory effects and to protect against neurodegeneration in models of neuroinflammation.

The development of PPAR未 as a drug target is an exciting area of research, and has the potential to revolutionize the treatment of a wide range of diseases. Further studies are needed to fully understand the mechanism of PPAR未 and to determine its safety and efficacy as a drug.

Protein Name: Rab Geranylgeranyltransferase Subunit Alpha

Functions: Catalyzes the transfer of a geranylgeranyl moiety from geranylgeranyl diphosphate to both cysteines of Rab proteins with the C-terminal sequence -XXCC, -XCXC and -CCXX, such as RAB1A, RAB3A, RAB5A and RAB7A

The "RABGGTA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RABGGTA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets